RPL31P20

Across TCGA pan-cancer cohorts, RPL31P20 RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated RPL31P20 data layer.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher RPL31P20 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL31P20 expression acts as an unfavorable survival marker.

READ, KIRC, and LIHC are the cancer types where RPL31P20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Tertile	IV	0.111	0.893	<.001	39	view →
KIRC	DFS	Tertile	III,IV	0.388	0.661	.018	36	view →
LIHC	DFS	Tertile	III,IV	0.061	0.364	<.001	27	view →
THCA	DFS	Tertile	IV	0.144	0.884	<.001	18	view →
GBM	DFS	Tertile	All	0.108	0.249	.048	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL31P20–READ (OS)

Open the READ breakdown →